In a show­down with As­traZeneca, Pfiz­er posts sol­id — and very fa­mil­iar — PhI­II breast can­cer da­ta for ta­la­zoparib

Pfiz­er $PFE came through with pos­i­tive num­bers for its Phase III study of its PARP in­hibitor ta­la­zoparib in ad­vanced breast can­cer — lin­ing up right along­side As­traZeneca’s $AZN lead­ing ri­val Lyn­parza. And the re­sults po­si­tion Pfiz­er to join the PARP line­up as the fourth play­er to toe up to the mar­ket thresh­old — though maybe not in the lead po­si­tion it was promised when the phar­ma gi­ant bought the drug last year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER